Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Second-Line Helicobacter Pylori Eradication
Sponsor: Seoul National University Bundang Hospital
Summary
Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).
Official title: Efficacy and Safety of Potassium-Competitive Acid Blocker-Bismuth Quadruple Therapy for Second-Line Helicobacter Pylori Eradication
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
141
Start Date
2021-02-01
Completion Date
2027-09-28
Last Updated
2026-10-02
Healthy Volunteers
No
Conditions
Interventions
P-CAB-BM quadruple regimen
Esomeprazole, amoxicillin, and moxifloxacin
Moxifloxacin triple regimen
Tegoprazan, amoxicillin, moxifloxacin, and bismuth
Locations (1)
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea